|Advancing HCV Drug Development: A Collaborative Approach|
DEC-06-10 A public meeting on HCV drug development was held Monday, December 6, 2010, in Washington, DC.
The Forum held this meeting to obtain public comments regarding future trial designs and endpoints, including evaluation of interferon and/or ribavirin sparing regimens and the use of two or more DAAs in treatment-naïve and treatment-experienced trials and in special populations. Additional issues encountered during the drug development process were also discussed.
The Forum brought together stakeholders from industry, patient advocates, academia, and regulators to discuss issues in clinical development of DAAs.
The Steering Committee for this project includes: